Related Experiment Video

Updated: Mar 6, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.4K

Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice

Richard W Joseph1, Gurkamal Chatta2, Ulka Vaishampayan3

  • 1Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL.

Urologic Oncology
|March 6, 2017
PubMed
Abstract

Insights

Nivolumab offers a novel treatment for advanced renal cell carcinoma (aRCC) by targeting the PD-1 immune checkpoint. This immunotherapy presents distinct efficacy and safety profiles compared to traditional therapies for aRCC.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Nivolumab represents a new therapeutic approach for advanced renal cell carcinoma (aRCC).
  • It functions as a programmed death 1 (PD-1) immune checkpoint inhibitor antibody.
  • Its mechanism of action differs from vascular endothelial growth factor (VEGF)-targeted therapies and mammalian target of rapamycin (mTOR) inhibitors.

Purpose of the Study:

  • To evaluate the clinical experience with nivolumab in aRCC based on existing literature.
  • To provide practical considerations for optimizing the clinical management of aRCC using nivolumab immunotherapy.

Main Methods:

  • Literature review and clinical experience evaluation.
  • Analysis of response patterns, efficacy, and safety profiles of nivolumab.
  • Discussion of practical aspects for clinical application in aRCC.

Main Results:

  • Nivolumab demonstrates distinct response patterns, efficacy, and safety compared to conventional treatments.
  • Clinical data suggests nivolumab as a viable option for advanced renal cell carcinoma.
  • The immunotherapy approach offers a different therapeutic profile.

Conclusions:

  • Nivolumab is a significant new therapy option for advanced renal cell carcinoma.
  • Understanding its unique properties is crucial for effective clinical management.
  • Immunotherapy with nivolumab provides an alternative to antiangiogenic and mTOR-targeted therapies.
Keywords:
Advanced renal cell carcinomaImmune checkpoint inhibitorImmunotherapy agentsNivolumabPD-1 inhibitorSecond-line therapy

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
1.4K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
547
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
698
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K